Lördag 21 December | 19:36:12 Europe / Stockholm

Bifogade filer

Kalender

Tid*
2025-02-28 08:00 Bokslutskommuniké 2024
2024-11-13 - Kvartalsrapport 2024-Q3
2024-08-21 - Kvartalsrapport 2024-Q2
2024-05-15 - Kvartalsrapport 2024-Q1
2024-03-28 - X-dag ordinarie utdelning CESSA 0.00 DKK
2024-03-27 - Årsstämma
2024-02-29 - Bokslutskommuniké 2023
2023-11-16 - Kvartalsrapport 2023-Q3
2023-08-24 - Kvartalsrapport 2023-Q2
2023-05-12 - Kvartalsrapport 2023-Q1
2023-03-24 - X-dag ordinarie utdelning CESSA 0.00 DKK
2023-03-23 - Årsstämma
2023-02-28 - Bokslutskommuniké 2022
2022-11-18 - Kvartalsrapport 2022-Q3
2022-11-04 - Extra Bolagsstämma 2022
2022-08-19 - Kvartalsrapport 2022-Q2
2022-04-19 - Kvartalsrapport 2022-Q1
2022-03-18 - X-dag ordinarie utdelning CESSA 0.00 DKK
2022-03-17 - Årsstämma
2022-02-24 - Bokslutskommuniké 2021
2021-11-19 - Kvartalsrapport 2021-Q3
2021-08-19 - Kvartalsrapport 2021-Q2
2021-04-19 - Kvartalsrapport 2021-Q1
2021-03-29 - X-dag ordinarie utdelning CESSA 0.00 DKK
2021-03-26 - Årsstämma
2021-02-11 - Bokslutskommuniké 2020

Beskrivning

LandDanmark
ListaSpotlight DK
SektorHälsovård
IndustriBioteknik
Cessatech är verksamt inom läkemedelsbranschen. Bolaget är specialiserat inom forskning och utveckling av smärtstillande nässpray som vidare används för behandling av akuta smärttillstånd hos barn. Utöver huvudverksamheten erbjuds även tillhörande kringtjänster och relaterade produkter. Verksamheten drivs globalt med störst närvaro inom den nordiska marknaden. Huvudkontoret ligger i Köpenhamn.
2023-03-23 14:00:00

The Board of Directors of Cessatech A/S ("Cessatech" or the "Company") has appointed Martin Olin as new Chairman of the Board

On 23 March 2023 Cessatech A/S announces that the Board of Directors has appointed Martin Olin as the Chairman of the Board. Martin Olin is CEO of BerGenBio and has been on the Board of Cessatech since August 2020. His biotech experience and knowledge of the company will be important as Cessatech moves into the next development for CT001. The previous Chairman of the Board, Adam Steensberg will continue as Board member of Cessatech. Martin Olin will be allocated additional 20,000 incentive warrants (in total 65,000) to the same level as previously allocated to the Chairman of the Board from the January 2023 allocation. Incentive warrant terms are the same as previously announced 17 January 2023

Comment from Martin Olin, Chairman of the Board of Directors, Cessatech
Since joining the Board of Directors, I have been truly impressed with the scientific rigor, quality and speed with which the company operates and look forward working with the Board, Jes Trygved and the team to progress our mission of bringing innovative new medicines to children.